Total trials
106
Active
40
Phase 3
1
Total enrollment
7,330
Pipeline matrix
Showing 2 of 2 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Optical Genome Mapping | — | — | — | — | — | 2 | |
| methyphenidate | — | — | — | — | — | 1 |
Next readouts
- 2026-12
- 2026-12
Top conditions
- Cerebral Palsy13
- Acquired Brain Injury10
- Autism Spectrum Disorder8
- Neurodevelopmental Disorders4
- Neurodevelopmental Disorder (Diagnosis)4
- Muscular Dystrophies4
- Developmental Dyslexia4
- Epilepsy4
Frequently asked questions about IRCCS Eugenio Medea
- How many clinical trials does IRCCS Eugenio Medea have on ClinicalTrials.gov?
- IRCCS Eugenio Medea is listed as the lead sponsor on 106 clinical trials in ClinicalTrials.gov, 40 of which are currently active (recruiting, enrolling, or ongoing).
- How many of IRCCS Eugenio Medea's trials are in Phase 3?
- 1 of IRCCS Eugenio Medea's trials are in Phase 3, spread across 2 active drug programs.
- What therapeutic areas does IRCCS Eugenio Medea focus on?
- IRCCS Eugenio Medea's most-studied conditions on ClinicalTrials.gov are Cerebral Palsy, Acquired Brain Injury, Autism Spectrum Disorder, Neurodevelopmental Disorders, Neurodevelopmental Disorder (Diagnosis).
- When are IRCCS Eugenio Medea's next clinical trial readouts?
- IRCCS Eugenio Medea has 2 upcoming primary-completion readouts tracked here; the soonest is “Expanding NGS Data with Optical Genome Mapping (OGM)”, expected around 2026-12.